On the third day of Chinese New Year, employees of Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. (Mingxing), GPHL’s leading TCM company with a history of 120 years, resumed production of the antiviral drug Qingkailing (QKL) for health care professionals.

QKL was one of the Chinese patent medicines recommended by Chinese healthcare authorities as a treatment for Severe Acute Respiratory Syndrome (SARS) in 2003. The QKL preparation is derived from a well-known classical formulation, An Gong Niu Huang Wan. It is a combination of eight main ingredients, including isatis root, honeysuckle flower and scutellaria, and has been shown to be an effective antibacterial, antiviral, and anti-inflammatory compound.

Mingxing employees work overtime to ensure the production and supply of Qingkailing.

The novel coronavirus (2019-nCoV) is from a similar family of viruses to SARS-CoV. Therefore, Mingxing’s QKL was selected as a recommended drug for fighting the pneumonia by local authorities, and complied into the Plan for Prevention and Control of the Novel Coronavirus Pneumonia Epidemic. On January 24th, QKL became an emergency drug for preventing and controlling the pneumonia outbreak caused by the virus in Guangzhou.

Due to the outbreak, patient and clinic demand of QKL saw a drastic increase, leading to the drug goingout-of-stock in many places. During the CNY holiday, Mingxing received an emergency drug order from Wuhan, Hubei province. Without further delay, the company delivered QKL to Wuhan by air.

He Guoxi pointed out that people’s health is Mingxing’s top priority, and that Mingxing has the utmost responsibility to safeguard it.

Author: Michelle, Monica

Editors: Simon, Olivia